Dohj LLC Invests $365,000 in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Dohj LLC purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 512 shares of the biopharmaceutical company’s stock, valued at approximately $365,000.

Other hedge funds have also bought and sold shares of the company. Northwestern Mutual Wealth Management Co. increased its stake in Regeneron Pharmaceuticals by 16.3% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 3,821 shares of the biopharmaceutical company’s stock valued at $4,016,000 after purchasing an additional 536 shares during the last quarter. B. Riley Wealth Advisors Inc. boosted its holdings in shares of Regeneron Pharmaceuticals by 8.0% in the 2nd quarter. B. Riley Wealth Advisors Inc. now owns 1,086 shares of the biopharmaceutical company’s stock valued at $1,142,000 after buying an additional 80 shares during the period. Clearbridge Investments LLC bought a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at about $1,506,000. Centaurus Financial Inc. acquired a new stake in Regeneron Pharmaceuticals during the second quarter worth about $118,000. Finally, Czech National Bank lifted its holdings in Regeneron Pharmaceuticals by 7.0% in the third quarter. Czech National Bank now owns 21,617 shares of the biopharmaceutical company’s stock worth $22,725,000 after acquiring an additional 1,405 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Down 1.5 %

REGN opened at $672.98 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. The company has a market capitalization of $73.95 billion, a PE ratio of 16.65, a P/E/G ratio of 1.62 and a beta of 0.10. The stock’s fifty day moving average is $720.81 and its 200-day moving average is $924.07. Regeneron Pharmaceuticals, Inc. has a one year low of $666.25 and a one year high of $1,211.20.

Analysts Set New Price Targets

REGN has been the subject of several recent research reports. Oppenheimer lowered their target price on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a report on Wednesday, November 6th. Truist Financial lowered their price objective on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a research note on Wednesday, January 8th. Royal Bank of Canada dropped their target price on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a research report on Friday, November 1st. Cantor Fitzgerald reissued a “neutral” rating and set a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 23rd. Finally, Canaccord Genuity Group cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, December 17th. One research analyst has rated the stock with a sell rating, seven have given a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $1,004.57.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.